GURUFOCUS.COM » STOCK LIST » USA » NAS » Moderna Inc (NAS:MRNA) » Definitions » Forward PE Ratio
Switch to:

Moderna Forward PE Ratio

: 7.82 (As of Today)
View and export this data going back to 2018. Start your Free Trial

Moderna's Forward PE Ratio for today is 7.82.

Moderna's PE Ratio without NRI for today is 5.31.

Moderna's PE Ratio for today is 5.31.


Moderna Forward PE Ratio Historical Data

The historical data trend for Moderna's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moderna Annual Data
Trend 2020-12 2021-12 2022-08
Forward PE Ratio
50.00 10.03 7.81

Moderna Quarterly Data
2020-09 2020-12 2021-03 2021-06 2021-09 2021-12 2022-03 2022-06
Forward PE Ratio 39.53 50.00 7.92 9.17 14.22 10.03 6.02 5.79

Competitive Comparison

For the Biotechnology subindustry, Moderna's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Moderna Forward PE Ratio Distribution

For the Biotechnology industry and Healthcare sector, Moderna's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Moderna's Forward PE Ratio falls into.



Moderna Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Moderna  (NAS:MRNA) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Moderna Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Moderna's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Moderna Business Description

Moderna logo
Address
200 Technology Square, Cambridge, MA, USA, 02139
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 44 mRNA development programs as of early 2022, with 25 of these in clinical trials. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Executives
Gomez Jorge M officer: See Remarks C/O DENTSPLY SIRONA INC 13320 BALLANTYNE CORPORATE PLACE CHARLOTTE NC 28277
Burton Paul officer: Chief Medical Officer 200 TECHNOLOGY SQUARE CAMBRIDGE MA 02139
Klinger Shannon Thyme officer: Chief Legal Officer 200 TECHNOLOGY SQUARE SUITE 300 CAMBRIDGE MA 02139
Le Goff Corinne officer: Chief Commercial Officer 200 TECHNOLOGY SQUARE SUITE 300 CAMBRIDGE MA 02139
Tallett Elizabeth E director 6705 ROCKLEDGE DR SUITE 900 BETHESDA MD 20817
Meline David W officer: Chief Financial Officer 3M COMPANY 3M OFFICE OF GENERAL COUNSEL ST PAUL MN 55144-1000
Horning Sandra director 333 LAKESIDE DRIVE FOSTER CITY CA 94404
Nader Francois director 550 HILLS DRIVE BEDMINSTER NJ 07921
Flagship Venturelabs Iv, Llc 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR CAMBRIDGE MA 02143
Sagan Paul director AKAMAI TECHNOLOGIES INC 8 CAMBRIDGE CENTER CAMBRIDGE MA 02142
Ruiz Israel director C/O FORTIVE CORPORATION 6920 SEAWAY BOULEVARD EVERETT WA 98203
Zaks Tal Zvi officer: Chief Medical Officer C/O ADAPTIMMUNE THERAPEUTICS PLC 60 JUBILEE AVE, MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX
Nabel Elizabeth G director BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS ST BOSTON MA 02115
Hoge Stephen officer: President C/O MODERNA, INC. 200 TECHNOLOGY SQUARE CAMBRIDGE MA 02139
Henderson Lori M. officer: General Counsel and Secretary MOLDFLOW CORP 430 BOSTON POST ROAD WAYLAND MA 01778

Moderna Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)